Trading in the ordinary shares of ERYTECH Pharma, was suspended at the request of the Company on November 10, 2017 from 9:00 am CET in connection with its previously announced global offering in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market.
